8-K
filed April 11, 2024, 7:59 PM ET
CIK 0001279695
other material
confidence high
sentiment neutral
materiality 0.70
Universal Biosensors launches A$10M underwritten entitlement offer at A$0.15/CDI with attaching options
UNIVERSAL BIOSENSORS INC
- Fully underwritten pro-rata non-renounceable offer of 1 new CDI per 3.47 existing at A$0.15, plus 1 option per CDI (A$0.20 exercise, 3-year term).
- Underwriter receives 13.85M options as fee; gross proceeds ~A$10M to fund growth, product development, operating losses, and Xprecia Prime sales after FDA approval.
- Stockholders approved increase in authorized common shares from 300M to 750M at April 10 special meeting.
- All four stockholder proposals passed: Underwriter Options, Placement CDIs, Placement Options, and Authorized Shares increase.
- Offer restricted to Australia/New Zealand resident holders; U.S. persons and other ineligible holders excluded.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
UNIVERSAL BIOSENSORS INC: Increased authorized shares of common stock from 300,000,000 to 750,000,000 (effective 2024-04-10).
- Change
- charter amendment
- Effective
- 2024-04-10
Exact text from the filing
the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of the Company’s common stock from 300,000,000 shares to 750,000,000 shares.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
UNIVERSAL BIOSENSORS INC entered into Underwriting Agreement with an underwriter valued at approximately A$10 million (effective 2024-04-11).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- an underwriter
- Value
- approximately A$10 million
- Effective
- 2024-04-11
Exact text from the filing
On April 11, 2024, Universal Biosensors, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with an underwriter named in the Underwriting Agreement (the “Underwriter”), whereby the Company agreed to issue: (i) up to 66,666,667 shares of its common stock in the form of CHESS Depositary Interests (“CDIs”)
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UNIVERSAL BIOSENSORS INC shareholders approved Authorized Shares Proposal at the 2024-04-10 meeting.
- Outcome
- passed
- Meeting
- 2024-04-10
Exact text from the filing
Proposal 4 Authorized Shares Proposal 108,416,353 2,323,110 1,307,106 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UNIVERSAL BIOSENSORS INC shareholders approved Underwriter Options Proposal at the 2024-04-10 meeting.
- Outcome
- passed
- Meeting
- 2024-04-10
Exact text from the filing
Proposal 1 Underwriter Options Proposal 52,880,699 2,603,610 55,808,640 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UNIVERSAL BIOSENSORS INC shareholders approved Placement CDIs Ratification Proposal at the 2024-04-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-04-10
Exact text from the filing
Proposal 2 Placement CDIs Ratification Proposal 103,092,909 7,643,449 1,310,211 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UNIVERSAL BIOSENSORS INC shareholders approved Placement Options Proposal at the 2024-04-10 meeting.
- Outcome
- passed
- Meeting
- 2024-04-10
Exact text from the filing
Proposal 3 Placement Options Proposal 102,831,014 7,908,449 1,307,106 —
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.